Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study-Reference-Cited by-同舟云学术

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Published:2022-04-05 Issue:2 Volume:149 Page:865-875
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Gursoy Pınar^ORCID,Tatli Ali Murat,Erdem Dilek,Goker Erdem^ORCID,Celik Emir,Demirci Nebi Serkan,Sakin Abdullah^ORCID,Atci Muhammed Mustafa^ORCID,Bayram Ertuğrul,Telli Tuğba Akın,Bilgin Burak,Bilici Ahmet,Akangunduz Baran,Balli Sevinç,Demirkazik Ahmet,Selçukbiricik Fatih,Menekse Serkan,Cavdar Eyyüp,Ozturk Akın,Bekmez Esma Türkmen,Turhal Serdal,Kilickap Sadettin,Yildirim Hasan Çağrı,Oyan Başak,Aksoy Asude,Turkoz Fatma Paksoy,Kut Engin,Katgi Nuran,Sakalar Teoman,Akyol Murat,Ellez Halil İbrahim,Topcu Atakan,Erdoğan Atike Pınar,Pilanci Kezban Nur,Hedem Engin,Arak Hacı,Akdeniz Nadiye,Alan Özkan,Yapar Burcu,Nart Deniz,Yumuk Perran Fulden

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-03984-5.pdf

Reference29 articles.

1. Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metéllus I, Lacave R, Lacroix L et al (2014) Rare EGFRexon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25:126–131

2. Byeon S, Kim Y, Won Lim S, Cho J-H, Park S, Lee J et al (2019) Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea. Cancer Res Treat 51(2):623–631

3. Chen D, Song Z, Cheng G (2016) Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther 2016(9):4181–4186

4. Chiu C-H, Yang C-T, Shih J-Y, Huang M-S, Su W-C, Lai R-S et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/ S768I mutations. J Thorac Oncol 10:793–9

5. Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C et al (2020) The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat rev 85:101994

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

2. Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18;Translational Lung Cancer Research;2024-04

3. Afatinib;Reactions Weekly;2023-03-11